TECP
FBRX icon

Trails Edge Capital Partners’s Forte Biosciences FBRX Stock Holding History

Trails Edge Capital Partners’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.81M Buy
+273,181
New +$6.48M 0.92% 32

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Trails Edge Capital Partners's FBRX Position: Q2 2026 in Review

Trails Edge Capital Partners opened a new position in Forte Biosciences (FBRX) in Q2 2026: 273,181 shares worth $5.81M. The stake represents 0.92% of the portfolio and ranks #32 among its holdings.

86 funds tracked by Wall St. Rank hold FBRX as of Q2 2026.

  • Trails Edge Capital Partners held 273,181 shares of Forte Biosciences worth $5.81M as of Q2 2026.
  • Forte Biosciences was a new Trails Edge Capital Partners position in Q2 2026.
  • Forte Biosciences made up 0.92% of Trails Edge Capital Partners's portfolio in Q2 2026, its #32 holding.
  • 86 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2026.

Based on Trails Edge Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.